Tag: LP1R
Dementia Risk Does Not Differ With GLP-1 RAs, DPP4is for Seniors With T2DM
Estimated risk ratio was lower with GLP-1 receptor agonists for those younger than 75 years, but was no different for those aged 75 years or older
GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD Complications
Risk ratios were 1.27 and 1.55 for GERD and its complications during a median follow-up of three years for GLP-1 RA versus SGLT-2 inhibitor users
Certain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist Treatment
Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction
Liraglutide May Reduce Migraine Burden in Adults With Obesity, Migraine
Decrease seen in mean monthly headache days and reduction in Migraine Disability Assessment scores
ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes
All three doses of orforglipron superior to placebo with respect to primary end point of change in HbA1c from baseline to week 40
Likelihood of Psych Disorders Lower With Weight-Loss Surgery Versus GLP-1 RAs
Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9 percent with early and late discontinuation and nondiscontinuation, respectively
GLP-1 Receptor Agonist Exposure Linked to Neovascular AMD in Patients With Diabetes
More than twofold increased risk seen for nAMD development in unadjusted and adjusted models
ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death
Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes
